CAMP4 THERAPEUTICS CORP (CAMP) Stock Fundamental Analysis

NASDAQ:CAMP • US13463J1016

4.52 USD
+0.18 (+4.15%)
Last: Feb 23, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall CAMP gets a fundamental rating of 3 out of 10. We evaluated CAMP against 521 industry peers in the Biotechnology industry. While CAMP seems to be doing ok healthwise, there are quite some concerns on its profitability. CAMP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CAMP had negative earnings in the past year.
  • In the past year CAMP has reported a negative cash flow from operations.
  • CAMP had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: CAMP reported negative operating cash flow in multiple years.
CAMP Yearly Net Income VS EBIT VS OCF VS FCFCAMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • CAMP has a Return On Assets (-61.48%) which is in line with its industry peers.
  • CAMP has a Return On Equity of -90.54%. This is comparable to the rest of the industry: CAMP outperforms 48.18% of its industry peers.
Industry RankSector Rank
ROA -61.48%
ROE -90.54%
ROIC N/A
ROA(3y)-66.31%
ROA(5y)-45.58%
ROE(3y)-87.52%
ROE(5y)-75.85%
ROIC(3y)N/A
ROIC(5y)N/A
CAMP Yearly ROA, ROE, ROICCAMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

  • CAMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAMP Yearly Profit, Operating, Gross MarginsCAMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K 20K 30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CAMP remains at a similar level compared to 1 year ago.
  • CAMP has more shares outstanding than it did 5 years ago.
  • CAMP has a better debt/assets ratio than last year.
CAMP Yearly Shares OutstandingCAMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CAMP Yearly Total Debt VS Total AssetsCAMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -0.03, we must say that CAMP is in the distress zone and has some risk of bankruptcy.
  • CAMP has a better Altman-Z score (-0.03) than 60.46% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that CAMP is not too dependend on debt financing.
  • The Debt to Equity ratio of CAMP (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.03
ROIC/WACCN/A
WACC8.71%
CAMP Yearly LT Debt VS Equity VS FCFCAMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 9.83 indicates that CAMP has no problem at all paying its short term obligations.
  • CAMP's Current ratio of 9.83 is amongst the best of the industry. CAMP outperforms 80.61% of its industry peers.
  • CAMP has a Quick Ratio of 9.83. This indicates that CAMP is financially healthy and has no problem in meeting its short term obligations.
  • CAMP's Quick ratio of 9.83 is amongst the best of the industry. CAMP outperforms 81.19% of its industry peers.
Industry RankSector Rank
Current Ratio 9.83
Quick Ratio 9.83
CAMP Yearly Current Assets VS Current LiabilitesCAMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 79.75% over the past year.
  • CAMP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -94.64%.
  • CAMP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -70.88% yearly.
EPS 1Y (TTM)79.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.73%
Revenue 1Y (TTM)-94.64%
Revenue growth 3Y-87.17%
Revenue growth 5Y-70.88%
Sales Q2Q%N/A

3.2 Future

  • CAMP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
  • CAMP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 211.05% yearly.
EPS Next Y68.61%
EPS Next 2Y35.94%
EPS Next 3Y22.99%
EPS Next 5Y13.67%
Revenue Next Year2386.14%
Revenue Next 2Y314.41%
Revenue Next 3Y79.12%
Revenue Next 5Y211.05%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CAMP Yearly Revenue VS EstimatesCAMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
CAMP Yearly EPS VS EstimatesCAMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CAMP. In the last year negative earnings were reported.
  • Also next year CAMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAMP Price Earnings VS Forward Price EarningsCAMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAMP Per share dataCAMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

  • CAMP's earnings are expected to grow with 22.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.94%
EPS Next 3Y22.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CAMP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (2/23/2026, 8:00:03 PM)

4.52

+0.18 (+4.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)05-11
Inst Owners58.81%
Inst Owner Change60.43%
Ins Owners1.32%
Ins Owner Change0.85%
Market Cap234.50M
Revenue(TTM)3.80M
Net Income(TTM)-53.12M
Analysts85
Price Target8.93 (97.57%)
Short Float %1.25%
Short Ratio2.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.59%
Min EPS beat(2)-12.73%
Max EPS beat(2)9.55%
EPS beat(4)2
Avg EPS beat(4)-56.84%
Min EPS beat(4)-237.33%
Max EPS beat(4)13.17%
EPS beat(8)3
Avg EPS beat(8)-285.46%
EPS beat(12)5
Avg EPS beat(12)-206.26%
EPS beat(16)8
Avg EPS beat(16)-154.85%
Revenue beat(2)2
Avg Revenue beat(2)97.25%
Min Revenue beat(2)49.89%
Max Revenue beat(2)144.61%
Revenue beat(4)4
Avg Revenue beat(4)950.01%
Min Revenue beat(4)49.89%
Max Revenue beat(4)3264.71%
Revenue beat(8)4
Avg Revenue beat(8)459.47%
Revenue beat(12)6
Avg Revenue beat(12)305.91%
Revenue beat(16)6
Avg Revenue beat(16)226.06%
PT rev (1m)0%
PT rev (3m)2.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.19%
EPS NY rev (1m)-7.16%
EPS NY rev (3m)-11.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)49.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)22.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.71
P/FCF N/A
P/OCF N/A
P/B 4
P/tB 4
EV/EBITDA N/A
EPS(TTM)-4.62
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.07
BVpS1.13
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.48%
ROE -90.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.31%
ROA(5y)-45.58%
ROE(3y)-87.52%
ROE(5y)-75.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.95%
Cap/Sales 14.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.83
Quick Ratio 9.83
Altman-Z -0.03
F-Score4
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)174.95%
Cap/Depr(5y)129.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.73%
EPS Next Y68.61%
EPS Next 2Y35.94%
EPS Next 3Y22.99%
EPS Next 5Y13.67%
Revenue 1Y (TTM)-94.64%
Revenue growth 3Y-87.17%
Revenue growth 5Y-70.88%
Sales Q2Q%N/A
Revenue Next Year2386.14%
Revenue Next 2Y314.41%
Revenue Next 3Y79.12%
Revenue Next 5Y211.05%
EBIT growth 1Y3.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.78%
EBIT Next 3Y-11.62%
EBIT Next 5YN/A
FCF growth 1Y-16.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.9%
OCF growth 3YN/A
OCF growth 5YN/A

CAMP4 THERAPEUTICS CORP / CAMP FAQ

What is the fundamental rating for CAMP stock?

ChartMill assigns a fundamental rating of 3 / 10 to CAMP.


What is the valuation status of CAMP4 THERAPEUTICS CORP (CAMP) stock?

ChartMill assigns a valuation rating of 1 / 10 to CAMP4 THERAPEUTICS CORP (CAMP). This can be considered as Overvalued.


Can you provide the profitability details for CAMP4 THERAPEUTICS CORP?

CAMP4 THERAPEUTICS CORP (CAMP) has a profitability rating of 1 / 10.


What is the financial health of CAMP4 THERAPEUTICS CORP (CAMP) stock?

The financial health rating of CAMP4 THERAPEUTICS CORP (CAMP) is 5 / 10.